<DOC>
	<DOC>NCT00741325</DOC>
	<brief_summary>This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3101 protocol (NCT00103610).</brief_summary>
	<brief_title>Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).</brief_title>
	<detailed_description>This is a long-term observational study of patients who received at least one dose of study treatment (plerixafor or placebo) in a multicenter, randomized, double blind, placebo-controlled investigational study to evaluate granulocyte colony stimulating factor (G-CSF) plus AMD3100 versus G-CSF plus placebo to mobilize and transplant Non-Hodgkin's Lymphoma (NHL) patients (protocol AMD3100-3101 [NCT00103610]). The objective of this study is to assess progression-free survival and overall survival of patients treated with at least 1 dose of study treatment (placebo or plerixafor) for a period of 5 years following the first dose of study treatment (placebo or plerixafor) in protocol AMD3100-3101 (NCT00103610).</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All patients who received a dose of study treatment (plerixafor or placebo)in protocol AMD31003101 (NCT00103610) No Exclusion Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>